CTLA4 and familial pancreatic carcinoma: In patients receiving CTLA-4 inhibitors, there is still a trend towards an increased risk of adverse reactions with the use of aspirin, but only with statistical significance in pancreatic cancer (OR 2.91, 95% CI 1.71–4.96, FDR adjusted p = 0.002) (Figure 8).